Special Issue "Advances in Medical Device Coatings"

Quicklinks

Special Issue Editors
Special Issue Information
Keywords
Published Papers
Planned Papers

A special issue of Coatings (ISSN 2079-6412).

Deadline for manuscript submissions: 20 September 2013

Special Issue Editor

Guest Editor
Dr. Denis Dowling
Surface Engineering Research Group, Room 223, UCD Engineering and Materials Science Centre, University College Dublin, Belfield, Dublin 4, Ireland
Website: http://www.ucd.ie/surfaces/staff_Denis_Dowling.htm
E-Mail: denis.dowling@ucd.ie
Phone: +353 (0)1 716 1747/1884/1787
Fax: +353 (0)1 283 0534
Interests: coatings; atmospheric plasmas; cell adhesion; medical devices; tailored surface chemistry

Special Issue Information

Dear Colleagues,

There has been an enormous growth in the application of coatings onto medical devices in the last few years. Examples of these coatings range from hydroxyapetite, which enhance cell attachment onto orthopaedic implants, to antimicrobial silver coatings on catheters, drug eluting coatings on stents and blood compatible coatings such as heparin. These coatings are deposited using processes such as plasma spraying, dipping and spin coating. More recently novel coating techniques such as laser treatments, low temperature atmospheric plasmas and microblasting techniques have also been developed for the deposition of bioactive coatings. The objective of this review is to highlight new developments in the deposition and characterisation of coatings for both implantable and non-implantable medical device applications. Issues such as how the presence of specific chemical functionalities or coating morphology influences protein and / or cell adhesion or anti-microbial activity will be considered. Developing methods of assessing the potential longer term stability (ageing) issues associated with coated devices are critically important prior to the clinical application of these devices. Included also in this review are both in-vitro and in-vivo studies on the performance of both novel coatings and / or processing technologies.

Dr. Denis Dowling
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Coatings is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

Keywords

coatings
thin film
biocompatibility
chemical functionality
cell attachment
surface treatment

Published Papers (3 papers)

Caroline O’Sullivan, Peter O’Hare, Greg Byrne, Liam O’Neill, Katie B. Ryan and Abina M. Crean

Article: A Modified Surface on Titanium Deposited by a Blasting Process

Coatings 2011, 1(1), 53-71; doi:10.3390/coatings1010053

Received: 16 July 2011; in revised form: 23 August 2011 / Accepted: 1 September 2011 / Published: 13 September 2011

Show/Hide Abstract | Download PDF Full-text (1194 KB) | Download XML Full-text

René Olivares-Navarrete, Jhon Jairo Olaya, Claudia Ramírez and Sandra Elizabeth Rodil

Article: Biocompatibility of Niobium Coatings

Coatings 2011, 1(1), 72-87; doi:10.3390/coatings1010072

Received: 2 August 2011; in revised form: 1 September 2011 / Accepted: 15 September 2011 / Published: 22 September 2011

Show/Hide Abstract | Download PDF Full-text (1391 KB) | Download XML Full-text

Johnson H. Y. Chung, Menno L. W. Knetsch, Leo H. Koole, Anne Simmons and Laura A. Poole-Warren

Article: Polyurethane Organosilicate Nanocomposites as Blood Compatible Coatings

Coatings 2012, 2(1), 45-63; doi:10.3390/coatings2010045

Received: 16 December 2011; in revised form: 20 February 2012 / Accepted: 22 February 2012 / Published: 27 February 2012

Show/Hide Abstract | Download PDF Full-text (1639 KB) | Download XML Full-text

Abstract: Polymer clay nanocomposites (NCs) show remarkable potential in the field of drug delivery due to their enhanced barrier properties. It is hypothesised that well dispersed clay particles within the polymer matrix create a tortuous pathway for diffusing therapeutic molecules, thereby resulting in more sustained release of the drug. As coatings for medical devices, these materials can simultaneously modulate drug release and improve the mechanical performance of an existing polymer system without introducing additional materials with new chemistries that can lead to regulatory concerns. In this study, polyurethane organosilicate nanocomposites (PUNCs) coated onto stainless steel wires were evaluated for their feasibility as blood compatible coatings and as drug delivery systems. Heparin was selected as the model drug to examine the impact of silicate loading and modifier chain length in modulating release. Findings revealed that better dispersion was achieved from samples with lower clay loadings and longer alkyl chains. The blood compatibility of PUNCs as assessed by thrombin generation assays showed that the addition of silicate particles did not significantly decrease the thrombin generation lag time (TGT, p = 0.659) or the peak thrombin (p = 0.999) of polyurethane (PU). PUNC coatings fabricated in this research were not cytotoxic as examined by the cell growth inhibition assay and were uniformly intact, but had slightly higher growth inhibition compared to PU possibly due to the presence of organic modifiers (OM). The addition of heparin into PUNCs prolonged the TGT, indicating that heparin was still active after the coating process. Cumulative heparin release profiles showed that the majority of heparin released was from loosely attached residues on the surface of coils. The addition of heparin further prolonged the TGT as compared to coatings without added heparin, but a slight decrease in heparin activity was observed in the NCs. This was thought to be from competitive interactions between clay-heparin that influenced the formation of the ternary complex between heparin, ATIII thrombin. In summary, the feasibility of using PUNC as drug delivery coatings was shown by the good uniformity in the coating, absence of by-products from the coating process, and the release of active molecules without significantly interfering with their activity.

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Biomedical Nanoparticle Surfaces: Insights into Immune-Compatibility
Authors: Olimpia Gamucci, Alice Bertero, Mariacristina Gagliardi and Giuseppe Bardi *
Affiliation: Center for MicroBioRobotics @SSSA, Istituto Italiano di Tecnologia, Viale Rinaldo Piaggio 34, 56025 Pontedera, Italy; E-Mail: Giuseppe.Bardi@iit.it (G.B.)
Abstract: Diagnostic- and therapeutic release-aimed nanoparticles require the highest degree of biocompatibility. Some physical and chemical characteristics of such nanomaterials are often at odds with this requirement. For instance, metals with specific features used as contrast agents in magnetic resonance imaging need particular coatings to improve their blood solubility and increase their biocompatibility. Other examples come from the development of nanocarriers exploiting the different characteristics of two or more materials, i.e., the ability to encapsulate a certain drug by one core-material and the targeting capability of a different coating surface. Furthermore, all these “human-non-self” modifications necessitate proofs of compatibility with the immune system to avoid inflammatory reactions and resultant adverse effects for the patient. In the present review we discuss the molecular interactions and responses of the immune system to the principal nanoparticle surface modifications used in nanomedicine

Last update: 23 May 2013

Coatings EISSN 2079-6412 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert